Drug-induced nonautoimmune hemolytic anemia

Drug-induced nonautoimmune hemolytic anemia
Synonyms
Pronounce	N/A
Specialty	N/A
Symptoms	Fatigue (medical), pallor, jaundice, dark urine, tachycardia
Complications	Acute kidney injury, heart failure
Onset
Duration
Types	N/A
Causes	Drug-induced hemolytic anemia
Risks
Diagnosis	Complete blood count, reticulocyte count, Coombs test
Differential diagnosis	Autoimmune hemolytic anemia, hereditary spherocytosis, G6PD deficiency
Prevention	Avoidance of triggering drugs
Treatment	Discontinuation of the offending drug, supportive care
Medication
Prognosis	Generally good with removal of the offending drug
Frequency	Rare
Deaths	N/A

Drug-induced nonautoimmune hemolytic anemia is a form of hemolytic anemia. Non-immune drug induced hemolysis can occur via oxidative mechanisms. This is particularly likely to occur when there is an enzyme deficiency in the antioxidant defense system of the red blood cells. An example is where antimalarial oxidant drugs like primaquine damage red blood cells in Glucose-6-phosphate dehydrogenase deficiency in which the red blood cells are more susceptible to oxidative stress due to reduced NADPH production consequent to the enzyme deficiency

This article is a stub. You can help WikiMD by registering to expand it. Editing is available only to registered and verified users. WikiMD is a comprehensive, free health & wellness encyclopedia.